AGA Guidelines on HCC Surveillance: Gastroenterology | May 2026
Introduction
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality in patients with cirrhosis. Despite advances in treatment, outcomes are largely determined by stage at diagnosis, making surveillance critical. Current strategies rely on ultrasound with AFP, but limitations in sensitivity and poor real-world uptake have created a need for better risk stratification and improved surveillance tools.
Why This Guideline Is Required
Traditional surveillance approaches are suboptimal due to:
Underuse in clinical practice
Limited sensitivity of ultrasound
Changing epidemiology (rise of MASLD and alcohol-related liver disease)
Lack of validated biomarkers and risk-based strategies
This guideline focuses on improving risk stratification, surveillance efficiency, and early detection.
20 Key Takeaways for Clinicians
- Prevention of cirrhosis is the most effective HCC strategy
Treat viral hepatitis, alcohol use, and metabolic syndrome early.
- Surveillance saves lives
Early detection improves access to curative therapies and survival.
- Standard surveillance = Ultrasound + AFP every 6 months
Still the recommended global standard.
Semiannual surveillance is superior to annual surveillance. It detects earlier-stage tumours and improves outcomes.
Ultrasound has limitations
Reduced sensitivity in obesity, MASLD, and advanced liver disease.
- AFP improves sensitivity when added to ultrasound
A combination is better than ultrasound alone.
- Surveillance is underutilised
Less than 25% of eligible cirrhosis patients undergo regular screening.
- Target population = All cirrhosis patients
Regardless of aetiology.
- Select non-cirrhotic HBV patients need surveillance
Based on age, ethnicity, and risk scores.
- No routine surveillance in non-cirrhotic MASLD or HCV
Unless better risk stratification tools are available.
- Surveillance not useful in limited life expectancy
Especially non-transplant candidates with advanced disease.
- Harms of surveillance must be considered
False positives, anxiety, cost, and unnecessary procedures.
- Biomarkers like GALAD are promising but not ready
Do not replace ultrasound + AFP yet.
- Liquid biopsy is the future—but still experimental
Requires validation in large prospective trials.
- Multicancer detection panels should NOT be used
Not validated for HCC surveillance populations.
- MRI has higher sensitivity, but is not routine
Cost, access, and practicality limit widespread use.
- Abbreviated MRI is promising
May become a future alternative in selected patients.
- Risk stratification is the future of surveillance
Not all cirrhosis patients have equal risk.
- Current risk models are imperfect
Limited validation and modest predictive performance.
- HBV risk scores (PAGE-B, REAL-B) are useful
Can guide surveillance decisions in non-cirrhotic HBV patients.
Practical Clinical Message
HCC surveillance is evolving from a uniform approach to a personalised strategy. While ultrasound + AFP remains the backbone, future progress will depend on risk-based surveillance, better biomarkers, and improved patient selection.
Conclusion
This guideline reinforces that current surveillance methods are effective but imperfect. The next phase in HCC care lies in precision surveillance, combining clinical risk, biomarkers, and imaging innovations to improve early detection while minimising harm.
